? SLRX – Daily Catalyst Report
Salarius Pharmaceuticals Inc.Salarius Pharmaceuticals Inc.
? Report Date:Report Date: November 12, 2025
⏰ Ora:Time: 12:37 PM CET
? Real-Time Update
Prezzo Attuale (Post-Market):Current Price (Post-Market):
$0.98 – $1.21
Movimento Oggi:Today’s Movement:
+23.7% (Pre-Mercato)(Pre-Market) | -51% (Intra-Day)(Intra-Day)
Volatilità:Volatility:
⚠️ ESTREMA (Penny Stock)
? Pan-Coronavirus Antiviral IND FilingPan-Coronavirus Antiviral IND Filing
Stimato: Q1-Q2 2026Est: Q1-Q2 2026
Decoy/SLRX pianifica di presentare una IND application per un agente antivirale pancoronavirus (copre COVID-19, futuri ceppi).
Decoy/SLRX plans to file IND for pan-coronavirus antiviral agent (covers COVID-19, future strains).
Impatto Potenziale:Potential Impact:
Alto (+150-300%)High (+150-300%)
⚠️ Rischio di Fallimento:Failure Risk:
Market affollato; competizione con Gilead, Roche, altri big pharmaCrowded market; competition with Gilead, Roche, other big pharma
? Seclidemstat Phase 1/2 Data Readout (MDS/CMML)Seclidemstat Phase 1/2 Data Readout (MDS/CMML)
Stimato: Q1-Q2 2026Est: Q1-Q2 2026
Trial investigator-initiator presso MD Anderson. Dati precedenti (Feb 2025): 43% response rate, 18.5 mesi median OS.
FDA clinical hold lifted (era sospeso luglio 2024).
Investigator-initiated trial at MD Anderson. Prior data (Feb 2025): 43% response rate, 18.5 months median OS.
FDA clinical hold lifted (was suspended July 2024).
Impatto Potenziale:Potential Impact:
Moderato (+80-120%)Moderate (+80-120%)
⚠️ Rischio:Risk:
Dati inferiori alle aspettative potrebbe causare -30-40%Below-expected data could cause -30-40%
? Broad-Acting Antiviral (RSV/FLU/COVID)Broad-Acting Antiviral (RSV/FLU/COVID)
Stimato: 2026-2027Est: 2026-2027
Decoy sviluppa terapia multi-target per RSV (Respiratory Syncytial Virus), Influenza, COVID-19.
Dati preclinici vs RSV e hPIV3 già completati.
Decoy developing multi-target therapy for RSV, Influenza, COVID-19.
Preclinical data vs RSV and hPIV3 already completed.
Impatto Potenziale:Potential Impact:
Altissimo se successo (+200-400%)Highest if successful (+200-400%)
⚠️ Rischio:Risk:
Ancora preclinical; non ha mai avuto farmaci approvati primaStill preclinical; no approved drugs to date
? GI Cancer PROTAC Drug CandidateGI Cancer PROTAC Drug Candidate
Stimato: 2026-2027Est: 2026-2027
SP-3164 (protein degrader SLRX) reformulato in PROTAC format per GI oncology.
Preclinical stage; nessun dato clinico ancora.
SP-3164 (SLRX protein degrader) reformulated into PROTAC format for GI oncology.
Preclinical stage; no clinical data yet.
Impatto Potenziale:Potential Impact:
Speculative (+50-150%)Speculative (+50-150%)
⚠️ Rischio:Risk:
Portfolio crowded di PROTAC competitoriCrowded portfolio of competing PROTACs
? Strategic Partnership / Licensing DealStrategic Partnership / Licensing Deal
Possibile: 2026-2027Possible: 2026-2027
Salarius sta “evaluating strategic alternatives” per seclidemstat.
Potenziale out-licensing con big pharma, partnership commerciale, o acquisition interest.
Salarius is “evaluating strategic alternatives” for seclidemstat.
Potential out-licensing with big pharma, commercial partnership, or acquisition interest.
Impatto Potenziale:Potential Impact:
Altissimo se annunciato (+300-500%)Highest if announced (+300-500%)
⚠️ Rischio:Risk:
Nessuna garanzia; potrebbe non succedere per anniNo guarantee; could take years or not happen
| CatalystCatalyst | TimelineTimeline | Bull CaseBull Case | Bear CaseBear Case |
|---|---|---|---|
| Pan-CoV IND FilingPan-CoV IND Filing | Q1-Q2 2026 | +150-300% | -50-70% |
| Seclidemstat DataSeclidemstat Data | Q1-Q2 2026 | +80-120% | -30-40% |
| Broad-Acting AntiviralBroad-Acting Antiviral | 2026-2027 | +200-400% | -60-80% |
| GI Cancer PROTACGI Cancer PROTAC | 2026-2027 | +50-150% | -40-60% |
| Strategic DealStrategic Deal | 2026-2027 | +300-500% | Neutral |
⚠️ RISCHI SPECIFICI DI $SLRXSPECIFIC RISKS FOR $SLRX
1. Diluzione Severa:1. Severe Dilution: Post-merger, investitori Decoy prendono il controllo + stock dilution attesaPost-merger, Decoy investors take control + expected stock dilution
2. Ultra-Volatile Penny Stock:2. Ultra-Volatile Penny Stock: Reverse split 1-for-15 ad agosto 2025; altissima volatilità1-for-15 reverse split in August 2025; extreme volatility
3. Capital Burn Alto:3. High Capital Burn: Dati attuali mostrano cash burn veloce; $7M finanziamento copre ~18-24 mesiCurrent data shows rapid cash burn; $7M financing covers ~18-24 months
4. Execution Risk:4. Execution Risk: Decoy è preclinical stage, nessun farmaco approvato mai. Tutto è teoricoDecoy is preclinical stage, no approved drugs ever. Everything is theoretical
5. Market Size Piccolo:5. Small Market Size: Pan-coronavirus antivirals è market very competitivoPan-coronavirus antivirals is highly competitive market
⚠️ DISCLAIMER:DISCLAIMER: Questo report è per scopi informativi only. $SLRX è ultra-volatile penny stock con rischio altissimo di perdita totale del capitale. Non è consiglio di investimento. Sempre fare due diligence proprio prima di qualsiasi decisione.This report is for informational purposes only. $SLRX is ultra-volatile penny stock with highest risk of total capital loss. Not investment advice. Always conduct own due diligence before any decision.